Avita Corporation 4735
TPEX · Taiwan · Health Services
TWD 36.00-0.05 (-0.14%)
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference. Vance, who has been CEO for about 10 months after previously serving
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results. President and Chief Executive Officer Cary Vance said the company’s U.S. RE
Avita Medical (NASDAQ:RCEL) executives told investors they are focused on making the business more predictable and execution-driven in 2026, following what they described as a headwind-heavy 2025 that included reimbursement disruption, a sales force reconfiguration, and repeated amendments tied to r
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.